Pain News and Research

Latest Pain News and Research

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Improved treatment after acute myocardial infarction and less severe patient profile have reduced 30-day mortality over the past 15 years, according to research presented at ESC Congress 2012.

29 Aug 2012

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

Johns Hopkins' Armstrong Institute for Patient Safety and Quality has received an $8.9 million grant from the Gordon and Betty Moore Foundation, the first award given as part of an ambitious new $500 million, 10-year program designed to eliminate all preventable harms that patients experience in the hospital.

29 Aug 2012

New treatment for severe dry eye is now available at U-M’s Kellogg

A new treatment available at the University of Michigan Kellogg Eye Center—prosthetic replacement of the ocular surface ecosystem or PROSE—provides relief to patients who suffer from severe dry eye, often the result of cancer or complex corneal disease.

29 Aug 2012

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Break apart a couple worm-like chromosomes and they may reconnect with mismatched tips and tails - such is the case of the EML4-ALK fusion gene that creates 2-7 percent of lung cancers. Almost exactly a year ago, the FDA approved the drug crizotinib to treat these ALK+ lung cancer patients, who were likely never smokers. Informed doctors use the test called a FISH assay to check for the EML4-ALK fusion gene, and then if the test is positive, ALK+ patients benefit greatly from crizotinib.

29 Aug 2012

Ultra-fast 320-detector CT scanner can accurately diagnose arterial blockages

An ultra-fast, 320-detector computed tomography (CT) scanner can accurately sort out which people with chest pain need - or don't need - an invasive procedure such as cardiac angioplasty or bypass surgery to restore blood flow to the heart, according to an international study. Results of the study, which involved 381 patients at 16 hospitals in eight countries, are scheduled to be presented at the European Society of Cardiology Congress in Munich, Germany, on August 28.

29 Aug 2012

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company focused on developing multi-indication therapeutics in oncology and CNS, today announced top-line results from a Phase II clinical study of Archexin, its clinical-stage oncology drug candidate.

29 Aug 2012

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

St. Jude Medical, Inc., a global medical device company, today announced that interim data demonstrated the company's EnligHTN renal denervation system is safe and effective for the treatment of resistant hypertension.

29 Aug 2012

Study looks at exercise habits among cancer patients

Numerous studies have shown the powerful effect that exercise can have on cancer care and recovery. For patients who have gone through breast or colon cancer treatment, regular exercise has been found to reduce recurrence of the disease by up to 50 percent.

29 Aug 2012

One in four women experience vulvar pain at some point in their lifetime

According to a study conducted by the University of Michigan, one in four women experience vulvar pain at some point in their lifetime. Like all medical concerns, vulvar pain causes both physical and mental stress. Additionally, vulvar pain can have an adverse effect on intimacy and relationships.

29 Aug 2012

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces positive headline results from the Phase 2 clinical trial of its lead product, EMA401, in postherpetic neuralgia (PHN), a painful condition that develops in some patients following herpes zoster (shingles) and where existing therapy does not relieve pain in all individuals.

28 Aug 2012

Major decline in early mortality for STEMI patients: French registries

Data from four French nationwide registries of STEMI (ST-elevation myocardial infarction) patients initiated five years apart and covering more than 15 years show that mortality rate decreased by 68% over this period, from 13.7% to 4.4%. Around one quarter of this mortality reduction could be attributed to a change in patient characteristics.

28 Aug 2012

Views on Medicare: Rep. Kathy Hochul's campaign; Ryan's vision; Wyden's role

Kathy Hochul is a young, first-term Democratic congresswoman fighting for her political life in a solidly Republican district outside Buffalo, N.Y. Unlike most of that liberal state, this is Romney country; a poll last week showed the GOP candidate ahead of President Obama in her district by a whopping 12 points.

28 Aug 2012

Community-based pharmacists could provide added resource in identifying knee OA

Canadian researchers have determined that community-based pharmacists could provide an added resource in identifying knee osteoarthritis (OA). The study, published in Arthritis Care & Research, a journal of the American College of Rheumatology (ACR), represents the first evidence supporting a collaborative approach to managing knee OA.

28 Aug 2012

Researchers develop glue mixture that may reduce risks after laser vision correction surgery

Kansas State University researchers have developed a glue mixture that may reduce risks after laser vision correction surgery.

28 Aug 2012

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Alder Biopharmaceuticals Inc. today announced it has received a $3.5 million milestone payment from Bristol-Myers Squibb for the initiation of a Phase 2 clinical trial of ALD518/BMS-945429, an investigational antibody therapeutic that blocks interleukin-6 (IL-6), in Crohn's disease.

28 Aug 2012

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Depomed, Inc. today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug delivery technology.

28 Aug 2012

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Merz, Inc. today announced the acquisition of CUVPOSA (glycopyrrolate) oral solution for pediatric chronic severe drooling associated with neurologic conditions such as cerebral palsy.

27 Aug 2012

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

The U.S. Food and Drug Administration (FDA) has notified Mallinckrodt, the pharmaceuticals business of Covidien, that it has approved a 32 mg tablet strength of EXALGO (hydromorphone HCI) Extended-Release Tablets (CII) for opioid-tolerant patients with moderate-to-severe chronic pain requiring continuous around-the-clock opioid analgesia for an extended period of time.

27 Aug 2012

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

RBC Life Sciences, Inc. announced today that the Company's stem cell supplement, Stem-Kine, has been approved for importation and sale in Taiwan. Stem-Kine is marketed in Taiwan under the name SK Plus.

27 Aug 2012

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, announced that additional data will be presented from its IMPRESS (The Investigation for Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, the phase III studies that assessed XIAFLEX (collagenase clostridium histolyticum or CCH), a novel, in-office, first-in-class biologic therapy for the potential treatment of Peyronie's disease (PD).

27 Aug 2012

Pain News and Research

Latest Pain News and Research

Study finds decline in 30-day mortality of acute myocardial infarction with improved treatment

Johns Hopkins' Armstrong Institute for Patient Safety and Quality receives Moore Foundation grant

New treatment for severe dry eye is now available at U-M’s Kellogg

FISH assay identifies only few lung cancer patients who could benefit from crizotinib

Ultra-fast 320-detector CT scanner can accurately diagnose arterial blockages

Top-line results from Rexahn’s Archexin Phase II study on metastatic pancreatic cancer

St. Jude’s EnligHTN renal denervation system safe and effective in treating resistant hypertension

Study looks at exercise habits among cancer patients

One in four women experience vulvar pain at some point in their lifetime

Positive results from Spinifex’s EMA401 Phase 2 trial on postherpetic neuralgia

Major decline in early mortality for STEMI patients: French registries

Views on Medicare: Rep. Kathy Hochul's campaign; Ryan's vision; Wyden's role

Community-based pharmacists could provide added resource in identifying knee OA

Researchers develop glue mixture that may reduce risks after laser vision correction surgery

Alder’s initiation of ALD518/BMS-945429 Phase 2 trial triggers $3.5M milestone payment

Janssen licenses rights to Depomed's Acuform gastric retentive drug delivery technology

Merz acquires CUVPOSA oral solution to treat children with cerebral palsy

Mallinckrodt receives FDA approval for 32 mg tablet strength of EXALGO

Taiwan approves RBC Life Sciences' Stem-Kine for importation and sale

Additional data from Auxilium XIAFLEX phase III studies on Peyronie's disease

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Pain News and Research

Latest Pain News and Research

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Newsletters you may be interested in